S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
NASDAQ:CLLS

Cellectis (CLLS) Stock Price, News & Analysis

$2.55
+0.08 (+3.24%)
(As of 04/19/2024 ET)
Today's Range
$2.51
$2.58
50-Day Range
$2.41
$3.03
52-Week Range
$0.96
$3.77
Volume
11,743 shs
Average Volume
31,645 shs
Market Capitalization
$141.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Cellectis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
233.3% Upside
$8.50 Price Target
Short Interest
Bearish
1.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.53) to ($1.06) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.44 out of 5 stars

Medical Sector

486th out of 911 stocks

Biological Products, Except Diagnostic Industry

75th out of 151 stocks

CLLS stock logo

About Cellectis Stock (NASDAQ:CLLS)

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

CLLS Stock Price History

CLLS Stock News Headlines

Cellectis (NASDAQ:CLLS) Rating Lowered to Sell at StockNews.com
Here’s how to start a “Weekend Side Hustle” from your sofa
Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.
Here’s how to start a “Weekend Side Hustle” from your sofa
Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.
Cellectis S.A. (CLLS)
Cellectis S.A. ADR
Cellectis SA ADR CLLS
Cellectis Non-GAAP EPS of -$0.58, revenue of $1.88M
Earnings Preview: Cellectis
See More Headlines
Receive CLLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/08/2021
Today
4/20/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CLLS
Employees
231
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$11.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+233.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-106,140,000.00
Net Margins
-346.65%
Pretax Margin
-320.53%

Debt

Sales & Book Value

Annual Sales
$25.73 million
Book Value
$2.76 per share

Miscellaneous

Free Float
46,463,000
Market Cap
$141.73 million
Optionable
Optionable
Beta
3.12
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Andre Choulika Ph.D. (Age 59)
    Co-Founder, CEO & Director
    Comp: $744.02k
  • Dr. David j. d. Sourdive Ph.D. (Age 57)
    Deputy CEO, Executive VP of CMC & Manufacturing and Director
    Comp: $528.92k
  • Dr. Bing C. Wang M.B.A. (Age 47)
    Ph.D., Chief Financial Officer
  • Valerie Cros
    Principal Financial Officer & Principal Accounting Officer
  • Mr. Jean Charles Epinat
    Chief Technological Officer
  • Dr. Philippe Duchateau Ph.D. (Age 61)
    Chief Scientific Officer
  • Mr. Stephan Reynier M.Sc. (Age 55)
    Chief Regulatory & Pharmaceutical Compliance Officer
  • Ms. Marie-Bleuenn Terrier (Age 42)
    General Counsel & Secretary of the Board of Directors
  • Pascalyne Wilson
    Director of Communications
  • Ms. Kyung Nam-Wortman (Age 54)
    Executive VP & Chief Human Resources Officer

CLLS Stock Analysis - Frequently Asked Questions

Should I buy or sell Cellectis stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLLS shares.
View CLLS analyst ratings
or view top-rated stocks.

What is Cellectis' stock price target for 2024?

2 Wall Street research analysts have issued twelve-month target prices for Cellectis' stock. Their CLLS share price targets range from $6.00 to $11.00. On average, they anticipate the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price.
View analysts price targets for CLLS
or view top-rated stocks among Wall Street analysts.

How have CLLS shares performed in 2024?

Cellectis' stock was trading at $3.08 at the start of the year. Since then, CLLS shares have decreased by 17.2% and is now trading at $2.55.
View the best growth stocks for 2024 here
.

When is Cellectis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CLLS earnings forecast
.

How were Cellectis' earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) issued its quarterly earnings data on Wednesday, December, 8th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by $0.02. Cellectis had a negative trailing twelve-month return on equity of 73.03% and a negative net margin of 346.65%.

What is André Choulika's approval rating as Cellectis' CEO?

13 employees have rated Cellectis Chief Executive Officer André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among the company's employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 39.0% of employees surveyed would recommend working at Cellectis to a friend.

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).

When did Cellectis IPO?

Cellectis (CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

How do I buy shares of Cellectis?

Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLLS) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners